EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
Background Analysis of cell-free DNA from blood could provide an alternative method for identifying genomic changes in the tumors of patients with advanced lung adenocarcinoma. Objective We compared the performance of droplet digital PCR (ddPCR) and Cobas ® EGFR Mutation Test v2 (Cobas) for detectin...
Saved in:
Published in | Targeted oncology Vol. 14; no. 2; pp. 197 - 203 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.04.2019
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Analysis of cell-free DNA from blood could provide an alternative method for identifying genomic changes in the tumors of patients with advanced lung adenocarcinoma.
Objective
We compared the performance of droplet digital PCR (ddPCR) and Cobas
®
EGFR Mutation Test v2 (Cobas) for detecting
EGFR
mutations in cell-free plasma DNA.
Patients and Methods
Plasma samples from patients with advanced
EGFR
-mutated lung adenocarcinoma were analyzed for
EGFR
T790M, exon 19 deletions, and L858R mutations by both ddPCR and Cobas.
Results
T790M testing was performed in 354 plasma samples collected from 129 patients. The concordance rate between ddPCR and Cobas for T790M, sensitivity, and specificity were 86, 100, and 85%, respectively. Exon 19 deletions were analyzed in 196 plasma samples obtained from 71 of the 129 patients using both platforms. The concordance rate between ddPCR and Cobas for exon 19 deletions, sensitivity, and specificity were 90, 92, and 89%, respectively. L858R mutations were studied in 124 plasma samples obtained from 44 of the 129 patients using both assays. The concordance rate between ddPCR and Cobas for L858R, sensitivity, and specificity were 90, 91, and 89%, respectively. In patients who progressed under treatment with an EGFR TKI (
n
= 50), the T790M positivity rate was 66% using ddPCR, but only 24% using Cobas.
Conclusions
We observed a high concordance between ddPCR and Cobas in detecting
EGFR
mutations in plasma samples of patients with advanced
EGFR
-mutated lung adenocarcinoma, but ddPCR was more sensitive than Cobas. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1776-2596 1776-260X |
DOI: | 10.1007/s11523-019-00623-x |